Kaposi's sarcoma tumor cells preferentially express Bcl-xL

Area of Science:

• Molecular Biology
• Cell Biology
• Dermatology

Background:

• Proteins like Bcl-2 and Bcl-x regulate programmed cell death (apoptosis).
• Bcl-x exists in long (Bcl-xL) and short (Bcl-xs) forms, influencing apoptosis differently.
• Endothelial cells (ECs) play a key role in angiogenesis.

Purpose of the Study:

• To investigate the expression levels of apoptosis-regulating proteins (Bcl-xL, Bcl-xs, Bcl-2) in benign and malignant proliferating endothelial cells (ECs).
• To determine the role of these proteins in skin disorders with angiogenic responses.

Main Methods:

• Immunohistochemical staining of skin samples from normal, psoriasis, pyogenic granuloma, and Kaposi's sarcoma patients.
• In vitro studies using cultured ECs and Kaposi's sarcoma tumor cells.
• Flow cytometry and immunoblot analysis of cultured cells.

Main Results:

• Normal quiescent ECs showed no expression of Bcl-xL, Bcl-xs, or Bcl-2.
• Diseased skin with angiogenic responses (psoriasis, pyogenic granulomas, Kaposi's sarcoma) showed marked overexpression of Bcl-xL in proliferating ECs and tumor cells, with little Bcl-2.
• Cultured ECs and Kaposi's sarcoma cells confirmed significantly higher Bcl-xL than Bcl-2 expression.

Conclusions:

• Overexpression of the cell survival protein Bcl-xL is a common feature in proliferating ECs within angiogenic skin disorders.
• This overexpression may contribute to the prolonged survival of EC-derived cells in these conditions.
• Bcl-xL is implicated in the pathogenesis of benign and neoplastic skin disorders characterized by prominent angiogenesis.